bluuebunny/crossref_metadata_2025_split huggingface dataset:
565-P: Vitamin D Supplementation Improves Anxiety and Depression Status in Elderly People with Prediabetes: An Open-Label 12-Month Randomized Controlled Study
Authors: ZAROMYTIDOU EVANGELIA , KOUFAKIS THEOCHARIS , DIMAKOPOULOS GEORGIOS , DRIVAKOU DESPOINA , MERISTOUDIS GEORGIOS , KONSTANTINIDOU STAVROULA , KARALIOLIOS GEORGIOS , MELIDOU EIRINI , RAKITZI PANTELITSA , GRAMMATIKI MARIA , MANTHOU ELENI , PSARRAKOU IOANNA S. , IAKOVOU IOANNIS , GOTZAMANI ANNA , KOTSA KALLIOPI 
Published: May 2022

Background: The combination of prediabetes and depressive or anxiety symptoms is known to increase the risk of progression to diabetes. We aimed to assess the effects of vitamin D supplementation on anxiety and depression status among elderly people with prediabetes.
Methods: Participants were randomly assigned to a weekly dose of vitamin D3 of 25,000 IU (n=45) or nothing (n = 45) , in addition to lifestyle measures. The State Trait Anxiety Inventory and the Patient Health Questionnaire-9 (PHQ-9) tools were used to evaluate anxiety and depression levels, respectively, at baseline, 6 and 12 months.
Results: Participants in the intervention and control group presented comparable baseline characteristics in terms of age (73.± 7.16 vs. 74.03 ± 7.64 years, respectively) , fasting glucose (103.4 ± 12.vs. 102.29 ± 12.82 mg/dl, respectively) and HbA1c values (5.87 ± 0.21 vs. 5.87 ± 0.22 %, respectively) . In the supplemented group, 25-hydroxyvitamin D concentrations increased significantly at 6 (26.56 ± 8.64 ng/ml) and 12 months (28.71 ± 9.03 ng/ml) compared to baseline (19.98 ± 6.73 ng/ml, p&lt;0.0 for both comparisons) . The mean trait anxiety scores were lower in supplemented individuals than the control group at 6 (38.02 ± 9.03 vs. 43.91 ± 7.18, respectively, p=0.003) and 12 months (32.35 ± 7.77 vs. 44.97 ± 7.78, respectively, p&lt;0.001) . The same pattern was evident for state anxiety scores at 6 (37.± 7.88 vs. 43.20 ± 9.33, p=0.003) and 12 months (32.59 ± 6.45 vs. 44.60 ± 9.53, p&lt;0.001) . Supplemented participants demonstrated lower mean PHQ-9 scores compared with controls at 6 (15.69 ± 6.15 vs. 19.77 ± 8.96, respectively, p=0.021) and 12 months (13.52 ± 5.vs. 20.20 ± 8.67, respectively, p&lt;0.001) .
Conclusion: In a high-risk population, a weekly vitamin D supplementation scheme was effective in reducing anxiety and depression levels. Further studies are needed to elucidate the relevant mechanisms.

Disclosure
E.Zaromytidou: None. M.Grammatiki: Research Support; Lilly. E.Manthou: None. I.S.Psarrakou: None. I.Iakovou: None. A.Gotzamani: None. K.Kotsa: Advisory Panel; Abbott, Novo Nordisk, Research Support; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Speaker's Bureau; AstraZeneca, Merck Sharp & Dohme Corp., Novartis AG, Sanofi. T.Koufakis: Advisory Panel; Novo Nordisk, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. G.Dimakopoulos: None. D.Drivakou: None. G.Meristoudis: None. S.Konstantinidou: None. G.Karaliolios: None. E.Melidou: None. P.Rakitzi: None.
57-OR: Responses to Lifestyle Intervention (LI) Are Associated to the Inter-Individual Variability in Glucose Metabolism at Baseline for Individuals at High Risk of Type 2 Diabetes (T2D)
Authors: SABATINI SILVIA , NOLAN JOHN J. , O'GORMAN DONAL , GASTALDELLI AMALIA 
Published: May 2022

LI can delay the onset of T2D. How inter-individual variability in response to LI relates to baseline phenotypic characteristics would help clinicians to advise on risk reduction. 328 subjects at high risk of T2D underwent a 12-weeks LI. Before and after LI, subjects were profiled for glucose and insulin measured through 75g-OGTT, peripheral (Matsuda (ISI) and HOMA) and hepatic (Hep-IR) insulin resistance indexes, insulinogenic index (IGI) , disposition index (DI=MI x dAUC0-180-Ins/glu) and target metabolomics. Hierarchical cluster analysis, based on indexes of insulin resistance (HOMA and ISI) and secretion (AUCins and IGI) , was performed to stratify the subjects at baseline. Pre vs. post values were compared in each cluster. Cluster analysis identified 4 groups with different degrees of glucose tolerance, insulin sensitivity and secretion (Figure A-D) , CL1 being the best. The 4 clusters showed different responses to LI: CL2-4 significantly improved insulin and reduced AUCins and α-ketoglutarate (p&lt;0.05) , while no significant changes in CL1 (Figure E) .
Conclusions: Hierarchical clustering identified phenotypes that might predict metabolic responses to LI.

Disclosure
S.Sabatini: None. J.J.Nolan: Consultant; My Way Digital Health, Speaker's Bureau; Novo Nordisk A/S. D.O'gorman: None. A.Gastaldelli: Advisory Panel; Boehringer Ingelheim International GmbH, Novo Nordisk Global Business Services, Consultant; Boehringer Ingelheim International GmbH, Inventiva Pharma, Other Relationship; Eli Lilly and Company, Gilead Sciences, Inc., Pfizer Inc., Speaker's Bureau; Novo Nordisk.
584-P: Who’s the Boss of Me? Autonomous vs. Controlled Motivation among Young Adults with T1D
Authors: PYATAK ELIZABETH , VIGEN CHERYL , SIDERIS JOHN , FOX D. STEVEN , DIAZ JESUS , ALI AINA , BLANCHARD JEANINE , GRANADOS GABRIELLE , SALAZAR ELIA , TAYLOR ELINOR , RAYMOND JENNIFER 
Published: May 2022

Introduction: Young adults (YAs) with T1D experience poorer self-care, psychosocial well-being and clinical outcomes relative to other age groups. A better understanding of factors that drive these challenges is needed to better support this age group. Behavioral science theory suggests that greater autonomous (vs. controlled) motivation (the degree to which behaviors are motivated by internal vs. external drivers) may enable YA to more effectively navigate the challenges of living with T1D.
Methods: Baseline surveys and clinical data from an ongoing self-management RCT were analyzed to examine associations between autonomous motivation (modified TSRQ) , glycemic control (HbA1c) , diabetes distress (DDS) , diabetes self-management (DSMQ) , self-efficacy (DES-SF) , and quality of life (ADD-QoL) . All analyses were adjusted for treatment regimen (injections/pump/CGM) .
Results: Among 133 YA with T1D (24.2±3.7 yrs, 53% female, 53% Latinx, 36% White, 11% multiethnic/other) , more autonomous motivation was associated with lower diabetes distress (standardized b= -0.19, p=0.04) and better self-management (b=0.18, p=0.04) . Analyses revealed that the association of autonomous motivation with lower diabetes distress scores was attributable to its associations with the emotional burden (b=-0.17, p=0.05) and regimen distress (b=-0.24, p=0.01) subscales, and its association with higher self management scores was driven by its association with the glucose monitoring subscale (b=0.32, p=0.0005) . Relationships between motivation and other measures were not significant.
Conclusion: Among YA with T1D, those with greater autonomous motivation for diabetes care had lower regimen distress and emotional burden, and greater glucose monitoring. While the causal direction of these relationships is unclear, it is plausible that interventions to enhance autonomous motivation may enhance self-management and well-being in this population.

Disclosure
E.Pyatak: Research Support; Abbott Diabetes. E.Taylor: None. J.Raymond: None. C.Vigen: n/a. J.Sideris: None. D.Fox: None. J.Diaz: None. A.Ali: None. J.Blanchard: None. G.Granados: None. E.Salazar: None.

Funding
National Institutes of Health (R01DK116719)
585-P: African-American Youth and Parent Perspectives on Advanced Technologies in Diabetes Management: Closing the Loop on Health Disparities
Authors: DELAMATER ALAN M. , PULGARON ELIZABETH R. , GUEVARA GABRIELA , WASHINGTON SONJA A. , FRANZ DIANE Z. , GOMEZ RICARDO , FELIPE DANIA , BHAT JAYALAKSHMI NARAYAN , CHALEW STUART 
Published: May 2022

Background: Research has shown that African American (AA) youth with type 1 diabetes (T1D) are at increased risk for suboptimal glycemic control, and less often utilize advanced technologies for diabetes management (DM) .
Objective: To better understand challenges to optimal DM for AA youth and willingness to use advanced technologies. Methods: Twenty-one AA youth with T1D and their parents participated in multi-family focus groups or individual family semi-structured interviews addressing barriers to DM and attitudes about new technologies such as the advanced hybrid closed loop (AHCL) insulin pump. Groups and interviews were recorded and conducted either in-person or using telehealth methods. Based on verbatim transcripts, content analysis was conducted using NVivo to develop a code book; two independent raters coded responses into themes and a third rater resolved discrepancies.
Results: The 21 youth participants (8 girls and 13 boys) had a mean age of 14.0 years and mean HbA1c of 9.6%; 16 (76%) had Medicaid; (47.6%) were using CGM and six (28.5%) had insulin pumps. Qualitative analyses revealed six main themes encompassing current regimens, life with diabetes, parenting, ethnicity, willingness to try new DM technologies, and hesitancy to utilize an AHCL system. Thirteen (62%) youth-parent dyads reported being very willing to try the AHCL system while just two (9.5%) reported they preferred to stay with their current regimen of injections and blood glucose checks; six dyads (28.5%) were open but not ready to commit, citing concerns about reliance on technology, potential side effects, and need for more information.
Conclusions: Innovative technology such as the AHCL insulin pump system may help to improve glycemic outcomes and reduce health disparities for AA youth. Many AA youth with T1D and their parents are ready to try advanced technologies but may require individualized support from the health care team to achieve optimal outcomes.

Disclosure
A.M.Delamater: None. E.R.Pulgaron: None. G.Guevara: None. S.A.Washington: None. D.Z.Franz: None. R.Gomez: None. D.Felipe: None. J.Bhat: None. S.Chalew: Advisory Panel; Medtronic.

Funding
National Institutes of Health (1R21DK118643)
596-P: Diabetes Responsibility Moderates Relationship between Fear of Hypoglycemia and A1C in Adolescents with Type 1 Diabetes
Authors: SHAFFER EMILY R. , O'DONNELL HOLLY K. , ALONSO GUY T. , MAJIDI SHIDEH , SNELL-BERGEON JANET K. , WADWA R. PAUL , DRISCOLL KIMBERLY A. 
Published: May 2022

Fear of hypoglycemia (FOH) is not consistently correlated with A1C in youth with T1D, but few studies have taken other psychosocial variables into account. This study examined T1D responsibility as a moderator of the relationship between FOH and A1C.
N=1youth ages 10-18 yrs (45.5% male; age=14.7±1.9 yrs; A1C=9.9±1.6%; T1D duration=6.5+3.4 yrs) completed the Maintain High Blood Glucose subscale of the Children’s Hypoglycemia Fear Survey (assesses behavioral manifestations of FOH) and Diabetes Family Responsibility Questionnaire (assesses distribution of T1D responsibility between child and caregiver) . Higher scores indicate greater FOH and caregiver responsibility, respectively.
The main effect of T1D responsibility on A1C was not significant (p&gt;0.05) , whereas the main effect of Maintain High Blood Glucose was (p=0.03) . Responsibility moderated the relationship between Maintain High Blood Glucose and A1C; child’s FOH had less of an effect on A1C if the caregiver had higher responsibility (B=-0.41, p=0.04; R2 =0.038, p&lt;0.04) .
Children who maintain their blood glucoses higher than recommended due to high FOH should have more parent involvement in their T1D care to minimize the deleterious impact of their fears on A1C. Future research should examine the Maintain High Blood Glucose subscale and other psychosocial moderators specifically in relation to glycemic outcomes.

Disclosure
E.R.Shaffer: None. H.K.O'donnell: None. G.T.Alonso: None. S.Majidi: None. J.K.Snell-bergeon: Stock/Shareholder; GlaxoSmithKline plc. R.Wadwa: Advisory Panel; Dompé, Consultant; Beta Bionics, Inc., Other Relationship; Tandem Diabetes Care, Inc., Research Support; Dexcom, Inc., Eli Lilly and Company, Tandem Diabetes Care, Inc. K.A.Driscoll: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK113363)
604-P: Self-Efficacy: Relationships with Diabetes Self-Care, Medication Adherence, and Diabetes Distress among Diverse Adults with Suboptimally Controlled Type 2 Diabetes (T2D)
Authors: FANG RAN , HOOGENDOORN CLAIRE J. , PAPPALARDO LINDSEY D. , MENDEZ-RODRIGUEZ HEIDY , WALKER ELIZABETH A. , GONZALEZ JEFFREY S. 
Published: May 2022

Background: Self-efficacy has been inconsistently operationalized in diabetes, with measures often failing to focus on confidence in one’s capacity to perform self-care. Measures that focus on confidence have been shown to be closely associated with self-care behaviors, but received limited psychometric evaluation and have not been examined in relation to diabetes distress.
Methods: We examined the reliability and factor structure of a previously published 8-item scale evaluating self-efficacy for diabetes self-care activities adapted by Sarkar and colleagues in 2006. We assessed cross-sectional relationships in baseline data with overall diabetes self-care, medication adherence, and diabetes distress among 812 predominantly Latino adults with T2D. They participated in a self-management support trial (Female = 56.9%; Latino = 86.5%) ; Mean (SD) Age and A1C = 59.2 (10.8) , 9.3 (1.8) , respectively.
Results: The scale demonstrated good internal reliability in the overall sample (α = .80) and among English (n = 179, α = .77) and Spanish (n = 633, α = .80) speakers. Exploratory factor analysis yielded a single factor, explaining 42% of the variance in self-efficacy scores. After adjusting for covariates, higher self-efficacy was independently associated with better diabetes self-care (β = .56, p &lt; .001) , better medication adherence (β = .30, p &lt; .001) , and lower diabetes distress (β = -.42, p &lt; .001) . Moderation analyses suggested consistency in these relationships across age, gender, SES, language, health literacy and numeracy.
Conclusions: To our knowledge, the factor structure of this diabetes self-efficacy scale has not been previously evaluated. Findings suggest self-efficacy is a robust correlate of T2D self-care, medication adherence, and distress. The scale is appropriate for predominantly disadvantaged English and Spanish speakers with varying health literacy and numeracy levels.

Disclosure
R.Fang: None. C.J.Hoogendoorn: None. L.D.Pappalardo: None. H.Mendez-rodriguez: None. E.A.Walker: None. J.S.Gonzalez: Consultant; Virta Health Corp.

Funding
National Institutes of Health (R18 DK098742) National Institutes of Health (RDK104845) National Institutes of Health (RDK121298) National Institutes of Health (RDK121896) Einstein-Mount Sinai Diabetes Research Center (P30 DK020541) New York Regional Center for Diabetes Translation Research (P30 DK111022)
606-P: What Do People with Type 1 Diabetes Think of a Fully Implantable Bionic Invisible Pancreas? A Qualitative Study
Authors: EHRMANN DOMINIC , FINKE-GROENE KATHARINA , KULZER BERNHARD , HERMANNS NORBERT 
Published: May 2022

The EU project “FORGETDIABETES” will develop a fully implantable automated insulin delivery (AID) system. It will consist of an intraperitoneal pump and an implantable CGM sensor. It aims at providing fully automated diabetes management with minimal user interaction. Semi-structured interviews to explore human factors of the bionic invisible pancreas (BIP) were conducted with people with type 1 diabetes. All participants provided written informed consent and were shown a video illustrating the components and functionality of the BIP. Participants were asked about aspects of life that could benefit from the BIP and aspects of life that could become more complicated. Interviews from 38 people were analysed. The most frequently mentioned aspect that could benefit was psychological with expected positive effects on quality of life, reduced diabetes distress, and less thinking about diabetes. Also, better glycaemic control and improvements regarding long-term complications were also frequently mentioned as aspects that could benefit. Aspects that might become more complicated related mostly to technical aspects (implantation procedure, taking an insulin pill, being dependent on the technology) . Loss of control was also a frequently named issue. Psychological aspects such as improvements in quality of life but also loss of control are important human factors for future AID systems.

Disclosure
D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. K.Finke-groene: Speaker's Bureau; Berlin-Chemie AG. B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care. N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi.

Funding
The present work was supported by H2020-FETPROACT Project FORGETDIABETS, n. 951933
636-P: The Effect of Cognitive Behavioral Therapy for Insomnia on Cardiometabolic Health: A Systematic Review of Randomized Controlled Trials
Authors: SAVIN KIMBERLY L. , CLARK TAYLOR , PEREZ-RAMIREZ PERLA , PARRA MAÍRA TRISTăO , GALLO LINDA 
Published: May 2022

Observational studies link poor sleep and insomnia with worse cardiometabolic health. Few studies have examined the effect of insomnia treatment on cardiometabolic health. This systematic review of randomized controlled trials (RCTs) aims to assess the effectiveness of Cognitive Behavioral Therapy for Insomnia (CBT-I) on cardiometabolic health. Medline, EMBASE, PsycINFO, and Cochrane CENTRAL databases were searched using relevant terms and articles were screened by two independent reviewers. Eligibility criteria were adult population, the delivery of CBT-I, reporting of ≥1 cardiometabolic health marker, and peer-review. Standardized mean differences (Cohen’s d) in outcomes between groups post-intervention were calculated. Studies were appraised for quality by two independent raters using the Cochrane Risk of Bias 2.0 tool. After screening 1290 articles, 13 unique studies (15 publications) met inclusion criteria. Markers of inflammation (CRP, IL-6, TNF-α) , systolic and diastolic blood pressure (SBP, DBP) , and glycemic regulation (HbA1c) were reported most frequently, in ≥3 studies each. Most studies that examined HbA1c and CRP found reductions in the CBT-I group compared to the control group and effect sizes ranged from small (d = -0.27) to medium (d = -0.66) . Effects varied widely for IL-6, TNF-α, SBP, and DBP, with most studies finding null results. Two studies were judged as having low risk of bias and the remaining as moderate to high risk of bias. CBT-I was most consistently associated with improvements in HbA1c and CRP, which are relatively temporally stable, suggesting that CBT-I may influence enduring habits rather than short term behavior changes. Interpretation of studies is limited by high risk of bias (e.g., baseline differences between groups despite randomization, lack of prespecified analytic plan) . High quality studies are needed to better understand and quantitatively synthesize effects.

Disclosure
K.L.Savin: None. T.Clark: None. P.Perez-ramirez: None. M.Tristăo parra: None. L.Gallo: None.
682-P: Feasibility of CGM Use in Basal-Bolus Insulin Therapy with an Electronic Decision Support System in Hospitalized Patients
Authors: BYTYQI KUJTIM , BAUMANN PETRA M. , HOCHFELLNER DANIEL A. , POETTLER TINA , SIMIC AMRA , BECK PETER , MADER JULIA K. 
Published: May 2022

Continuous glucose monitoring (CGM) provides a more holistic picture of glycemic control than capillary blood glucose (BG) measurements. We simulated CGM use with a clinical decision support system (cDSS) with a basal-bolus insulin algorithm using CGM values recorded at the same time (CGM0) vs. 15 minutes after the BG measurement (CGM+15) to simulate typical CGM trend information.
Data of 30 inpatients with T2D (age: 74.1±10.9 years, female: 60 %, Caucasian: 100 %, BMI: 28.6±5.6 kg/m2, diabetes duration: 13.2±11.6 years, HbA1c: 72±22 mmol/mol, stay duration: 8.2±3.7 days) were used. Simulation results were analysed for insulin doses, overall glycemic control, and potentially avoidable hypoglycemic events (PAHE) : those occurring within 3 hours of a bolus insulin injection when the suggested dose based on CGM was lower.
Glucose levels and insulin doses were lower when using CGM. Glucose differences were mainly due to nocturnal hypoglycemia undetected by BG (Table 1) . 36 PAHEs occurred in 17 patients with CGM0 vs. 38 PAHEs in patients with CGM+15. In the simulation, lower CGM readings and undetected nocturnal hypoglycemia resulted in lower insulin doses (single and total daily doses) . Consequently, there were hypoglycemic events that could have been avoided had CGM been used. Combining cDSS and CGM is feasible and can facilitate glycemic control whilst avoiding hypoglycemia.

Disclosure
K.Bytyqi: None. P.M.Baumann: None. D.A.Hochfellner: None. T.Poettler: None. A.Simic: None. P.Beck: Employee; decide Clinical Software GmbH, Stock/Shareholder; decide Clinical Software GmbH. J.K.Mader: Advisory Panel; Abbott Diabetes, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Speaker’s Bureau; Abbott Diabetes, Eli Lilly and Company, Medtronic, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Roche Diabetes Care, Sanofi-Aventis Deutschland GmbH, Servier Laboratories, Stock/Shareholder; decide Clinical Software GmbH.
691-P: Evaluation of an Implantable CGM System Using a Multiple-Analyte Indicator Hydrogel for Calibration Reduction
Authors: VELVADAPU VENKATA N. , MASCIOTTI JAMES M. , DEHENNIS ANDREW D. , SANCHEZ PATRICIA , TWEDEN KATHERINE S. , KAUFMAN FRANCINE R. , IOACARA SORIN 
Published: May 2022

Background: The Eversense CGM System sensor is implanted in the upper arm. It uses a fluorescent, boronic acid glucose-binding moiety to measure glucose. The glucose indicator is susceptible to oxidative de-boronation from reactive oxygen species (ROS) in the interstitial fluid, necessitating daily calibrations. To reduce calibration frequency, a ROS indicator was added to measure oxidative de-boronation. Figure 1 (a) shows the copolymerization of glucose and ROS indicators into a single hydrogel matrix with orthogonal excitation emission properties. The sensor uses a 380 nm LED for excitation of the glucose indicator and a 470 nm LED for excitation of the ROS indicator.
Methods: The fluorescence of the indicators was characterized in vitro. In addition, sensors were implanted in subjects with type 1 diabetes in a 365-day clinical feasibility study to assess accuracy against fingerstick measurements.
Results: Figure 1 (b) illustrates the relationship whereby ROS exposure increases the fluorescence of the ROS indicator and decreases the fluorescence of the glucose indicator. A MARD of 9.9% against fingerstick with one calibration per week was observed through 90 days.
Conclusions: Early data suggests the multiple-analyte system should allow the next generation of long-term, implanted CGM systems to maintain accuracy with significantly reduced calibration requirements.

Disclosure
V.N.Velvadapu: None. J.M.Masciotti: Employee; Senseonics. A.D.Dehennis: Employee; Senseonics. P.Sanchez: Employee; Senseonics. K.S.Tweden: Employee; Senseonics. F.R.Kaufman: Consultant; Twin Health, Employee; Senseonics. S.Ioacara: Research Support; Senseonics.